Usefulness of Stereotactic Radiotherapy Using the CyberKnife for Patients with Inoperable Locoregional Recurrences of Differentiated Thyroid Cancer

• Published in: World journal of surgery 2019-02, Vol.43 (2), p.513-518
• Main Authors: Ishigaki, Takayuki, Uruno, Takashi, Tanaka, Tomoaki, Ogimi, Yuna, Masaki, Chie, Akaishi, Junko, Hames, Kiyomi Y., Yabuta, Tomonori, Suzuki, Akifumi, Tomoda, Chisato, Matsuzu, Kenichi, Ohkuwa, Keiko, Kitagawa, Wataru, Nagahama, Mitsuji, Sugino, Kiminori, Ito, Koichi
• Format: Article
• Language: English
• Subjects: Abdominal Surgery; Cancer; Cardiac Surgery; Feasibility studies; General Surgery; Information systems; Irradiation; Lesions; Medical records; Medicine; Medicine & Public Health; Original Scientific Report (including Papers Presented at Surgical Conferences); Ostomy; Paralysis; Patients; Radiation dosage; Radiation therapy; Salvage; Surgery; Thoracic Surgery; Thyroid; Thyroid cancer; Tracheostomy; Vascular Surgery
• ISSN: 0364-2313; 1432-2323
• DOI: 10.1007/s00268-018-4813-5

Background Surgical resection is the preferred treatment for locoregional recurrence of differentiated thyroid cancer (DTC). However, some recurrences are unresectable because of their aggressive invasion or severe adhesions. On the other hand, stereotactic radiotherapy (SRT) enables high-dose irradiation to target lesions, and its usefulness for various cancers has been reported. The objective of the present study was to investigate the feasibility and efficacy of SRT as salvage treatment for locoregional recurrence of DTC. Methods Between August 2011 and December 2017, 52 locoregional recurrent lesions in 31 patients with recurrent DTC were treated by SRT using the CyberKnife system. Information on the adverse events associated with SRT was retrospectively collected from the patients’ medical records. Of the 52 lesions, 33 could be evaluated for therapeutic effectiveness by follow-up CT, and response was assessed using the RECIST criteria. Results Twenty-five patients had papillary carcinoma, 5 had follicular carcinoma, and 1 had poorly differentiated cancer. SRT was delivered in one to 20 fractions, and the median dose was 30 Gy (range 15–60 Gy). Adverse events were not frequent, but 1 patient developed bilateral vocal cord palsy that required emergent tracheostomy. The median follow-up period of 33 lesions was 14 months (range 1–54 months). Complete response, partial response, stable disease, and progressive disease were seen in 10, 11, 9, and 3 patients, respectively. The 3-year local control rate was 84.6%. Conclusion SRT using the CyberKnife system was found to be a feasible and effective treatment to suppress the growth of locoregional recurrence of DTC.